The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Launches Intestinal Amebiasis Treatment on April 12
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
- Sanofi K.K. Sales Grew 5.7% in 2012, Plavix Enjoys Sales Success
April 11, 2013
- Ethical Drug Sales Fall 1.7% in February as Flu Season Slows Down: Crecon Report
April 11, 2013
- Teva Pharma Voluntarily Recalls Enalapril Maleate Tablets
April 11, 2013
- Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
- Fujimoto’s Safety Procedures TERMS Takes Effect April 1, Celgene’s RevMate June 1
April 10, 2013
- Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
- Trazenta Now Stands at Starting Line Without Concurrent Use Restrictions: NBI President Aono
April 10, 2013
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
- Eisai Sets Up Sales Subsidiary in Russia
April 9, 2013
- Ajinomoto Acquires US-Based Althea Technologies to Expand Biotech Operations
April 9, 2013
- Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
- Astellas Collaborates with Ambrx for Discovery and Development of Novel ADCs for Oncology Fields
April 9, 2013
- Novo Nordisk’s FY2012 Sales Dip 0.8% with Insulin Market Subdued by DPP-4 Inhibitors
April 8, 2013
- Abbott Japan Sales Decline 3.2% in 2012 Due to Product Transfer to AbbVie
April 8, 2013
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…